Status:
RECRUITING
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Lead Sponsor:
Peking University First Hospital
Conditions:
Multiple Myeloma
Amyloidosis
Eligibility:
All Genders
Brief Summary
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be...
Detailed Description
Primary 1. To establish a prospective cohort of patients with PCDs in PKUFH. 2. To dynamically analyze the relation between MRD status and prognosis, and the possible role of TME in PCD patients. Se...
Eligibility Criteria
Inclusion
- Patients included are those with confirmed diagnosis of PCDs and hospitalized into Peking University First Hospital (PKUFH)
- Patients of plasma cell disorders (PCDs) are recruited. PCDs include monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple myeloma; plasma cell leukemia; amyloidosis; light chain deposition disease; heavy chain deposition disease; Castleman's disease (CD); Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes syndrome; cryoglobulinemia; Monoclonal Gammopathy of Renal Significance (MGRS); Monoclonal gammopathy of neurological significance (MGNS).
- Patients are included into this cohort after signing the ICFs.
Exclusion
- Significant comorbidity may be life-threatening.
Key Trial Info
Start Date :
July 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT05283993
Start Date
July 1 2021
End Date
December 31 2030
Last Update
April 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, China